Conmed (CNMD) Tops Q2 View By 2c; Reducing Guidance
More News related to CNMD
- CONMED Corporation to Present at the 21st Annual Piper Jaffray Health Care Conference
- CONMED Linvatec Announces Launch of Novel Biocomposite Technology and Related Matryx(TM) Biocomposite Interference Screws
- CONMED Linvatec Announces Launch of Bullseye(TM) Anatomic Cruciate Reconstruction System
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
- CONMED Corporation to Announce Third Quarter 2009 Financial Results on October 22, 2009
Conmed (Nasdaq: CNMD) reports Q2 EPS of $0.17, 2 cents better than the analyst estimate of $0.15. Revenue for the quarter was $164.6 million, versus the consensus of $163.04 million.
Reducing sales guidance by $10.0 million to $670 - $680 million versus $671.34M and the non-GAAP EPS guidance by $0.07 to $0.85 - $0.95 versus consensus of $0.94.
Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!
Related Categories
EarningsGuidance
Stocks Mentioned
-0.74Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
